.avif)
Summarize with:
Some studies need approval from two committees before the first participant can be enrolled. The most common case is human gene transfer research, which requires review by both the Institutional Biosafety Committee (IBC) and the Institutional Review Board (IRB). Each committee looks at a different risk: the IBC at the recombinant or synthetic nucleic acid material and its handling, the IRB at the protection of research participants. When the two reviews run without coordination, studies wait on paperwork rather than on substance. This post covers which studies need both, where dual review stalls and how to sequence it.
Key takeaways
- Human gene transfer studies need IBC and IRB approval before enrollment. Other studies may need both because of infectious agents or biological materials used with participants.
- Most delays come from late IBC intake and from changes approved by one committee but not the other.
- Running the two reviews in parallel, with shared checkpoints, usually beats running them one after the other.
- Track both approvals, and every amendment, against the same study so nothing is implemented early.
Which Studies Need Both IBC and IRB Review?
The clearest trigger is human gene transfer. Under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules , these experiments need IBC approval before participants are enrolled, and the study also needs IRB approval for the human subjects side. Institutions that receive NIH funding for this kind of research apply the NIH Guidelines to it.
Other studies can need both reviews too, depending on institutional policy. Examples include clinical studies that administer live attenuated vaccines or other biological agents, research that collects samples likely to contain infectious agents, and work involving genetically modified cells given to participants.
The rule of thumb is simple. If the protocol introduces a biological agent or recombinant material into people, or exposes staff to one, the IBC should see it.
Where Does Dual Review Stall?
Dual review rarely fails because either committee is slow. It fails at the points where the two processes meet.
- The IBC learns of the study late. The investigator submits to the IRB first, and biosafety review only starts when someone notices the gene transfer component. The IBC becomes the longest step in study activation.
- The committees ask for the same information twice. Investigators describe the agent, the procedures and the personnel in two different forms, and the answers do not quite match.
- Changes approved by one committee are not sent to the other. An amendment that changes the dose, route or product can need IBC review as well as IRB review. If only one committee sees it, the study team may implement a change that is not fully approved.
- Status is scattered. Study teams, sponsors and the clinical research office cannot see in one place whether both approvals are in hand.
- Personnel and training are tracked separately. Biosafety training and human subjects training are recorded in different places, so it is hard to confirm everyone on the study is cleared for both.
Each of these delays activation or creates a compliance gap. Offices running older systems see the same problems as offices on paper when IBC and IRB information sits in systems that do not share it.
How Should IBC and IRB Reviews Be Sequenced?
The most reliable approach is parallel review with shared checkpoints: open both reviews at intake, share core study information, and allow enrollment only when both approvals are complete.
- Flag dual review at intake. Add screening questions to the IRB submission (and the IBC registration) that identify recombinant material, biological agents or gene transfer. A yes opens the other committee's review automatically or alerts its staff.
- Share core study information once. Protocol, investigator brochure, product description and personnel list should be visible to both committees, so investigators answer common questions one time.
- Review in parallel. Each committee completes its own review against its own requirements. Neither committee needs to wait for the other to begin.
- Exchange determinations. Each committee's approval, required modifications and conditions should be visible to the other, because a change requested by one can affect the other's review.
- Hold enrollment until both approvals are in place. The clinical research office or study team confirms both approvals before activation. The system can show outstanding items, but the institution decides when the study opens.
Some institutions prefer the IBC to review first for high-risk products, so the IRB sees the biosafety determination before its own deliberation. That is a reasonable policy choice. What matters is that the order is written down and applied consistently.
What to Track Across Both Committees
Once a dual-review study is approved, the work continues. Track these items against the same study:
- Approval dates and expiration or renewal dates for each committee
- Amendments, with a note of which committee each one needs
- Adverse events and incidents, since some must be reported to both committees and, for biosafety incidents, to NIH
- Personnel changes and training status for both biosafety and human subjects requirements
- Closure, so both committees close the study together
An IBC protocol software tool and an IRB system that can see each other's status make this tracking far less manual. Without that, keep one shared tracking list owned by a named coordinator.
What Should a System Support for Dual Review?
Whether you are replacing IBC protocol software or extending your IRB system, judge it against the dual-review workflow you actually run.
- Intake screening. Can submission questions identify recombinant material or biological agents and open the other committee's review?
- Shared study information. Can both committees see the same protocol, product description and personnel list without investigators submitting them twice?
- Visible determinations. Can IBC staff see IRB status and conditions, and the reverse, inside their own workflow?
- Amendment routing. Can an amendment be routed to one or both committees based on what it changes?
- Combined training status. Can coordinators confirm biosafety and human subjects training for everyone on the study in one view?
- Reporting. Can the office list every active dual-review study with both approval dates and upcoming renewals?
Confirm these before selection with a scripted demonstration of one real dual-review study. Gaps in biosafety and IRB integration are hard to close once a system is live.
Where Key Solutions Fits
eProtocol by Key Solutions supports both committees through its Biosafety (IBC) and Human Subjects (IRB) modules, for institutions that review studies with both components.
The system supports the process. The principal investigator remains responsible for the protocol, and each committee remains responsible for its own determination.
